• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

二代酪氨酸激酶抑制剂作为一线治疗药物引入后慢性髓性白血病治疗方式和结局的变化:CML 合作研究组的一项多机构回顾性研究。

Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group.

机构信息

Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi Kami-cho, Itabashi-ku, Tokyo, 173-8610, Japan.

Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan.

出版信息

Int J Hematol. 2024 Jul;120(1):60-70. doi: 10.1007/s12185-024-03758-4. Epub 2024 Apr 8.

DOI:10.1007/s12185-024-03758-4
PMID:38587692
Abstract

This study investigated changes in treatment modalities and outcomes of chronic myeloid leukemia in the chronic phase (CP-CML) after the approval of second-generation tyrosine kinase inhibitors (2G-TKIs) for first-line therapy. Patients were grouped into those who underwent TKI therapy up to December 2010 (imatinib era group, n = 185) and after January 2011 (2G-TKI era group, n = 425). All patients in the imatinib era group were initially treated with imatinib, whereas patients in the 2G-TKI era group were mostly treated with dasatinib (55%) or nilotinib (36%). However, outcomes including progression-free survival, overall survival, and CML-related death (CRD) did not differ significantly between groups. When stratified by risk scores, the prognostic performance of the ELTS score was superior to that of the Sokal score. Even though both scoring systems predicted CRD in the imatinib era, only the ELTS score predicted CRD in the 2G-TKI era. Notably, the outcome of patients classified as high-risk by ELTS score was more favorable in the 2G-TKI era group than in the imatinib era group. Thus, expanding treatment options may have improved patient outcomes in CP-CML, particularly in patients classified as high-risk by ELTS score.

摘要

这项研究调查了第二代酪氨酸激酶抑制剂(2G-TKIs)获批用于一线治疗后,慢性期慢性髓性白血病(CP-CML)的治疗方式和结局变化。患者分为接受 TKI 治疗至 2010 年 12 月(伊马替尼时代组,n=185)和 2011 年 1 月后(2G-TKI 时代组,n=425)的两组。伊马替尼时代组所有患者最初均接受伊马替尼治疗,而 2G-TKI 时代组患者大多接受达沙替尼(55%)或尼洛替尼(36%)治疗。然而,两组患者的无进展生存期、总生存期和 CML 相关死亡(CRD)等结局均无显著差异。按风险评分分层时,ELTS 评分的预后性能优于 Sokal 评分。尽管两种评分系统均能预测伊马替尼时代的 CRD,但只有 ELTS 评分能预测 2G-TKI 时代的 CRD。值得注意的是,ELTS 评分高危患者的结局在 2G-TKI 时代组比伊马替尼时代组更有利。因此,扩大治疗选择可能改善了 CP-CML 患者的结局,尤其是 ELTS 评分高危患者。

相似文献

1
Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group.二代酪氨酸激酶抑制剂作为一线治疗药物引入后慢性髓性白血病治疗方式和结局的变化:CML 合作研究组的一项多机构回顾性研究。
Int J Hematol. 2024 Jul;120(1):60-70. doi: 10.1007/s12185-024-03758-4. Epub 2024 Apr 8.
2
Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.伊马替尼400mg、伊马替尼800mg、达沙替尼和尼洛替尼用于慢性期慢性髓性白血病患者的长期分子和细胞遗传学反应及生存结果:来自五项临床试验患者数据的回顾性分析
Lancet Haematol. 2015 Mar;2(3):e118-28. doi: 10.1016/S2352-3026(15)00021-6. Epub 2015 Mar 20.
3
Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?索卡尔或 EUTOS 长期生存(ELTS)评分是否能更好地预测接受酪氨酸激酶抑制剂治疗的慢性髓性白血病患者的反应和结局?
Leukemia. 2022 Feb;36(2):482-491. doi: 10.1038/s41375-021-01387-y. Epub 2021 Aug 19.
4
The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort.EUTOS 长期生存评分可预测基于实践队列的慢性髓系白血病患者的疾病特异性死亡率和分子反应。
Cancer Med. 2020 Dec;9(23):8931-8939. doi: 10.1002/cam4.3516. Epub 2020 Oct 10.
5
Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States.美国慢性髓性白血病患者酪氨酸激酶抑制剂治疗模式的真实世界分析。
Clin Ther. 2015 Jan 1;37(1):124-33. doi: 10.1016/j.clinthera.2014.10.019. Epub 2014 Nov 22.
6
[Treatment status of tyrosine kinase inhibitor for newly-diagnosed chronic myeloid leukemia: a domestic multi-centre retrospective real-world study].酪氨酸激酶抑制剂治疗初诊慢性髓性白血病的现状:一项国内多中心回顾性真实世界研究
Zhonghua Xue Ye Xue Za Zhi. 2024 Mar 14;45(3):215-224. doi: 10.3760/cma.j.cn121090-20231108-00255.
7
Prognostic effect of comorbidities in patients with chronic myeloid leukemia treated with a tyrosine kinase inhibitor.酪氨酸激酶抑制剂治疗慢性髓性白血病患者合并症的预后影响。
Cancer Sci. 2020 Oct;111(10):3714-3725. doi: 10.1111/cas.14580. Epub 2020 Aug 12.
8
Sequential use of second-generation tyrosine kinase inhibitors following imatinib therapy in pediatric chronic myeloid leukemia: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.伊马替尼治疗后序贯二代酪氨酸激酶抑制剂在儿童慢性髓性白血病中的应用:来自日本儿科白血病/淋巴瘤研究组的报告。
Pediatr Blood Cancer. 2018 Dec;65(12):e27368. doi: 10.1002/pbc.27368. Epub 2018 Aug 7.
9
Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase.异基因造血干细胞移植对比尼罗替尼和达沙替尼治疗加速期成年慢性髓性白血病患者的优越性。
Front Med. 2015 Sep;9(3):304-11. doi: 10.1007/s11684-015-0400-4. Epub 2015 Jun 22.
10
Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.接受酪氨酸激酶抑制剂治疗的慢性髓性白血病患者的估计肾小球滤过率变化
Cancer. 2015 Nov 1;121(21):3894-904. doi: 10.1002/cncr.29587. Epub 2015 Jul 28.

引用本文的文献

1
Prognostic scoring systems in chronic myeloid leukaemia.慢性髓性白血病的预后评分系统
Leukemia. 2025 May;39(5):1046-1052. doi: 10.1038/s41375-025-02606-6. Epub 2025 Apr 15.

本文引用的文献

1
Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities.美国国立综合癌症网络(NCCN)和欧洲白血病网络(ELN)的慢性髓性白血病治疗指南:差异与相似之处
Int J Hematol. 2023 Jan;117(1):3-15. doi: 10.1007/s12185-022-03446-1. Epub 2022 Sep 5.
2
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.2022年欧洲心脏病学会/欧洲呼吸学会肺动脉高压诊断和治疗指南。
Eur Respir J. 2023 Jan 6;61(1). doi: 10.1183/13993003.00879-2022. Print 2023 Jan.
3
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial.
博舒替尼对比伊马替尼用于初诊慢性期慢性髓性白血病:BFORE 试验的最终结果。
Leukemia. 2022 Jul;36(7):1825-1833. doi: 10.1038/s41375-022-01589-y. Epub 2022 May 28.
4
Long-term outcomes of patients with Chronic Myeloid Leukemia who commenced treatment with imatinib: a 20-year single-centre experience.开始使用伊马替尼治疗的慢性髓性白血病患者的长期结局:一项为期20年的单中心经验。
Leuk Lymphoma. 2022 Sep;63(9):2213-2223. doi: 10.1080/10428194.2022.2068000. Epub 2022 May 2.
5
Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network.慢性髓性白血病患者总生存的预后因素:意大利慢性髓性白血病GIMEMA网络的一项多中心队列研究
Front Oncol. 2021 Aug 26;11:739171. doi: 10.3389/fonc.2021.739171. eCollection 2021.
6
Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow‑up of the Japanese subgroup of the randomized ENESTnd trial.尼洛替尼与伊马替尼治疗日本新诊断慢性期慢性髓性白血病患者的疗效比较:随机ENESTnd试验日本亚组的10年随访
Int J Hematol. 2022 Jan;115(1):33-42. doi: 10.1007/s12185-021-03216-5. Epub 2021 Sep 11.
7
Chronic myeloid leukaemia.慢性髓性白血病。
Lancet. 2021 Nov 20;398(10314):1914-1926. doi: 10.1016/S0140-6736(21)01204-6. Epub 2021 Aug 20.
8
Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?索卡尔或 EUTOS 长期生存(ELTS)评分是否能更好地预测接受酪氨酸激酶抑制剂治疗的慢性髓性白血病患者的反应和结局?
Leukemia. 2022 Feb;36(2):482-491. doi: 10.1038/s41375-021-01387-y. Epub 2021 Aug 19.
9
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.一线尼洛替尼对比伊马替尼治疗初诊慢性期慢性髓性白血病的长期疗效:ENESTnd 研究 10 年分析。
Leukemia. 2021 Feb;35(2):440-453. doi: 10.1038/s41375-020-01111-2. Epub 2021 Jan 7.
10
The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort.EUTOS 长期生存评分可预测基于实践队列的慢性髓系白血病患者的疾病特异性死亡率和分子反应。
Cancer Med. 2020 Dec;9(23):8931-8939. doi: 10.1002/cam4.3516. Epub 2020 Oct 10.